← Back to headlines
Aurinia Pharmaceuticals Targets $305M–$315M LUPKYNIS Sales for 2026
Aurinia Pharmaceuticals aims for LUPKYNIS sales between $305 million and $315 million in 2026, as it continues to advance the clinical development of voclosporin.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
